2014 Fiscal Year Final Research Report
Investigation for the mechanism of anti-cancer drugs resistance and therapeutic strategy in multiple myeloma
| Project/Area Number |
24590224
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Kinki University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
TSUBAKI Masanobu 近畿大学, 薬学部, 講師 (30434856)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Keywords | 抗癌剤耐性 / 分子標的薬 / 多発性骨髄腫 |
|---|
| Outline of Final Research Achievements |
To investigate the underlying mechanisms associated with resistance to anti-cancer drugs, we established anti-cancer drug-resistant multiple myeloma (MM) cell lines. The resistant cell lines overexpressed MDR1 and survivin, or showed decreased Bim expression through activation of Src. In addition, dasatinib reversed the drug-resistance of the drug-resistant cell lines. These findings suggest that Src inhibitors are potentially useful as an anti-MDR agent for the treatment of malignant tumor cells.
As well, These results are summarized as section of presented paper.
|
| Free Research Field |
医療薬学
|
